Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tony van Werkhooven who wrote (601)	3/4/1999 6:03:00 PM
From: Dr. John M. de Castro	Read Replies (2) of 1386

This is a rather remarkable statement in the Q4 release. "The Company is also gearing up for Phase III trials in the US and Europe for dexanabinol, its lead compound for neurological diseases and disorders." Would they be doing this without a partner? I interpret "gearing up" to mean designing the trial, talking with the FDA about the design and end points, finding clinical sites, etc. I can't imagine PARS doing this without the close concurrence of a partner. It wouldn't make any sense to be going forward without the close participation of a partner in the planning. This suggests to me that an agreement may be a lot closer than many of us thought. But, then this may simply be wishful thinking on my part :-) John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next